deltatrials
Completed PHASE3 INTERVENTIONAL 6-arm NCT02924688

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma

Sponsor: GlaxoSmithKline

Conditions Asthma
Interventions Albuterol/salbutamol DISKUS DPI ELLIPTA DPI FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC) METERED-DOSE INHALER (MDI)
Updated 30 times since 2017 Last updated: Feb 26, 2021 Started: Oct 13, 2016 Primary completion: Feb 22, 2019 Completion: Feb 22, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. GlaxoSmithKline leads this study, which shows 30 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Mar 2020 · 11 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE3

▶ Show 25 earlier versions

  1. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Apr 2019 — Mar 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Nov 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  9. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  10. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  11. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  12. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  13. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  14. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  15. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  16. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  17. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  18. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  19. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  20. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  21. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  22. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  23. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  24. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  25. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Abingdon, United States , Adairsville, United States , Aichi, Japan , Ajax, Canada , Alcobendas, Spain , Alkmaar, Netherlands , Almere Stad, Netherlands , Anderson, United States , Arkhangelsk, Russia and 284 more locations